Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioCryst (BCRX – Research Report) today. The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, ...
On Monday, BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $8.19 which represents a slight increase of $0.41 or 5.27% from the prior close of $7.78. The stock opened ...
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback